

CIGOGNE FUND

M&A Arbitrage
31/07/2023



Assets Under Management :

149 103 417 €

Net Asset Value (O Shares) : € 45 872.26


PERFORMANCES

	January	February	March	April	May	June	July	August	September	October	November	December	YTD
2023	0.19%	0.49%	-3.30%	1.06%	-2.92%	2.80%	1.59%						-0.25%
2022	0.33%	0.80%	0.86%	-0.52%	-1.95%	-1.60%	2.13%	1.99%	-1.18%	-1.06%	-0.04%	0.57%	0.22%
2021	1.16%	0.30%	1.08%	1.58%	1.62%	-0.19%	-2.38%	-0.49%	0.60%	0.35%	-0.38%	1.04%	4.30%
2020	0.41%	-1.12%	-8.71%	4.30%	-1.03%	-1.94%	3.05%	0.91%	-0.82%	1.69%	1.94%	0.69%	-1.24%
2019	-0.66%	-0.19%	0.03%	-0.24%	-0.81%	-0.32%	0.77%	-0.06%	0.73%	0.90%	1.11%	1.17%	2.43%


PORTFOLIO STATISTICS SINCE 31/12/2004 AND FOR 5 YEARS

	Cigogne M&A Arbitrage		Euribor 1M		HFRX Global Hedge Fund EUR Index	
	5 years	From Start	5 years	From Start	5 years	From Start
Cumulative Return	2.78%	358.15%	-0.04%	16.80%	-5.13%	-8.89%
Annualised Return	0.55%	8.53%	-0.01%	0.84%	-1.05%	-0.50%
Annualised Volatility	6.41%	9.61%	0.31%	0.44%	4.96%	5.46%
Sharpe Ratio	0.09	0.80	-	-	-0.21	-0.25
Sortino Ratio	0.12	2.01	-	-	-0.29	-0.32
Max Drawdown	-9.73%	-14.71%	-1.91%	-2.87%	-12.07%	-25.96%
Time to Recovery (m)	12	> 40	> 11	> 11	13	> 40
Positive Months (%)	55.00%	72.65%	18.33%	59.64%	51.67%	56.95%

PERFORMANCE (Net Asset Value)



DISTRIBUTION OF RETURNS (Monthly Basis)




INVESTMENT MANAGERS' COMMENTARY

The summer period started out quiet in terms of new operations. The main announcements, which were made official over the last few days of July, related to American target companies for more than \$6 billion. Investment opportunities have therefore emerged for Reata Pharmaceuticals, following the offer made by Biogen, and for New Relic, a specialist in web analysis and monitoring, as part of its privatisation plan launched by a consortium made up of Fransisco Partners Management and TPG.

July was a good month for data and our portfolio was able to benefit from important developments with several major holdings. First of all, the Black Night and Intercontinental Exchange groups have taken an important step in their \$14.1-billion merger by entering into an agreement to sell the Optimal Blue company owned by the target company. This sale simplifies the merger, as it is the second sale made by Black Night to address anti-trust concerns raised by the FTC. Although it quickly narrowed, the spread is still wide enough to maintain the position, pending future discussions between the entities and the decision-making body. In addition, as one of the largest holdings by size, the takeover of the giant VMware by Broadcom, for more than \$70 billion, obtained, within a 7-day window, provisional approval from the European Union and then from the British regulatory authority, the UK CMA. In order to do so, Broadcom has proposed interoperability solutions to certain competitors, and must now defend its operation with the FTC, as part of the second phase of the study. Finally, while a California judge authorised Microsoft to conclude its acquisition of Activision Blizzard, by overruling the FTC's argument, the giants decided to extend their merger contract by three months so that they could once again defend their merger with the CMA. While Microsoft had appealed the English regulator's initial decision to block the merger, the latter suggested that a restructured deal could address its concerns, subject to further study.

Portfolio leverage remained relatively stable in July. The closures of the Iveric Bio and VectivBio Holdings operations, but especially of several operations in the small cap segment, have been replaced by strategies relating to Reata Pharmaceuticals and New Relic, cited in the introduction, and to the British legal services provider, DWF Group.

ASSET BREAKDOWN



CORRELATION MATRIX

	Cigogne M&A Arbitrage	Euribor 1M	HFRX Global Hedge Fund EUR Index
Cigogne M&A	100.00%	-1.14%	69.59%
Euribor 1M	-1.14%	100.00%	-0.53%
HFRX HF Index	69.59%	-0.53%	100.00%

CIGOGNE FUND

M&A Arbitrage

31/07/2023



INVESTMENT OBJECTIVES

The choice of the assets is guided by an arbitration of mergers and/or acquisitions, consisting in benefiting from the price differences, which can appear at the time of takeover bids or exchange. Based on a solid and detailed analysis of the economic, legal and competitive frameworks, initiated operations are mainly held until the finalization of the offer. The portfolio only focuses on declared M&A situations. Initiated strategies consist in acquiring shares of the target company (cash offer) and selling shares of the acquirer (stock, cash and stock offer) or conversely if we expect the bid to fail. The sub-fund may also develop strategies on corporate action arbitrage such as preferential subscription rights.

FUND SPECIFICS

Net Asset Value :	€	149 103 417.13
Net Asset Value (O Units) :	€	31 194 163.25
Liquidative Value:	€	45 872.26
ISIN Code :		LU0648563830
Legal Structure :		FCP - SIF, AIF
Inception Date of the fund :		November 16th 2004
Inception Date (O Units) :		November 16th 2004
Currency :		EUR
NAV calculation date :		Monthly, last calendar day of the month
Subscription / redemption :		Monthly
Minimum Commitment:	€	125 000.00
Minimum Notice Period:		1 month

MAIN EXPOSURES (In percentage of gross asset base)

SIMCORP	3.70%
ACTIVISION BLIZZARD	3.28%
SEAGEN	3.17%
HORIZON THERAPEUTICS	2.91%
SILICON MOTION TECHNOLOGY	2.55%

Management Fee:	1,50% per annum
Performance Fee :	20% above €STR with a High Water Mark

Country of Registration :	FR, LU
Management Company:	Cigogne Management SA
Investment Advisor:	CIC Marchés
Depository Bank:	Banque de Luxembourg
Administrative Agent:	UI efa
Auditor:	KPMG Luxembourg

RISK PROFILE



The risk category has been determined on the basis of historical data and may not be a reliable indication of the future risk profile. The risk and reward category shown does not necessarily remain unchanged and the categorization of the fund may shift over time.

REASONS TO INVEST IN CIGOGNE M&A ARBITRAGE

In addition to traditional financial investment, alternative investments aim to provide investors with absolute performances independent from the return of traditional asset classes such as shares, bonds etc. With these objectives, alternative investments can be construed as the natural complement to assets allocation between classical portfolio investment and risks managed performance strategies that take advantages of market inefficiencies.

Cigogne Management S.A. is the alternative asset management branch of Crédit Mutuel Alliance Fédérale, a major actor in the industry. Cigogne Management S.A. benefits from CIC Marchés' deep expertise. Cigogne Management S.A. currently manages the Cigogne Fund, Cigogne UCITS and Cigogne CLO Arbitrage funds (single-strategy funds) as well as the Stork Fund (multi-strategy funds).

Cigogne Fund - M&A Arbitrage aims to achieve stable and positive performances over time, uncorrelated from traditional asset classes by setting up arbitrage strategies taking advantage of disrupted and modified interest rate curves.

DISCLAIMER

The information contained herein is provided for information purposes only and shall only be valid at the time it is given. No guarantee can be given as to the exhaustiveness timeliness or accuracy of this information. Past performance is no indication of future returns. Any investment may generate losses or gains. The information on this document is not intended to be an offer or solicitation to invest or to provide any investment service or advice. Potentially interested persons must consult their own legal and tax advisor on the possible consequences under the laws of their country of citizenship or domicile. Any person must carefully consider the suitability of their investments to their specific situation and ensure that they understand the risks involved. Subscriptions to fund shares will only be accepted on the basis of the latest prospectus and the most recent annual reports.

CONTACT

CIGOGNE MANAGEMENT S.A.

18 Boulevard Royal
L - 2449 Luxembourg
LUXEMBOURG

www.cigogne-management.com

contact@cigogne-management.com

